title: [Treatment of refractory asthma with antibodies].
abstract: Current guidelines of the global initiative for asthma (GINA) recommend the addition of biologics in step 5 of the stepwise asthma treatment approach. This review gives an overview on the effects and the clinical role of antibodies targeting immunoglobulin E, IgE (Omalizumab), Interleukin-5, IL-5 (Mepolizumab, Reslizumab) or the IL-5 receptor (Benralizumab). In addition, potential future treatment options of refractory asthma with antibodies (for instance Dupilumab) are discussed.
authors.forename: Marek
authors.initials: M
authors.lastname: Lommatzsch
mesh_terms: D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D019983:Guideline Adherence; D006801:Humans; D007073:Immunoglobulin E / Q000187:drug effects; D015848:Interleukin-5 / Q000037:antagonists & inhibitors; D000069444:Omalizumab / Q000009:adverse effects / Q000627:therapeutic use; D057285:Precision Medicine; D053649:Receptors, Interleukin-5 / Q000037:antagonists & inhibitors
chemical_list: D018927:Anti-Asthmatic Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508599:IL5 protein, human; D015848:Interleukin-5; D053649:Receptors, Interleukin-5; D000069444:Omalizumab; C515492:reslizumab; D007073:Immunoglobulin E; C582203:dupilumab; C571386:benralizumab; C434107:mepolizumab